EMMPRIN expression in oral SCC is regulated by FYN kinase

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1205-1209

  Ramos, Daniel M ^a   Dang, Dongmin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ECM; EMMPRIN; FYN; Integrin; Oral SCC

Indexed keywords

BETA6 INTEGRIN; CAVEOLIN 1; CD147 ANTIGEN; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE FYN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANTIGEN EXPRESSION; ARTICLE; CARCINOMA CELL; COMPLEX FORMATION; ENZYME ACTIVATION; LIGAND BINDING; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANTIGENS, CD147; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CAVEOLIN 1; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; MATRIX METALLOPROTEINASE 14; MITOGEN-ACTIVATED PROTEIN KINASES; MOUTH NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FYN;

EID: 79956154769     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Silverman SJ: Oral Cancer. B.C. Decker Ontario, pp. 1-148, 1998.
2. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM and Noel A: Membrane type 1 metalloprotease (MT1-MMP) is a transmembrane metalloprotease that plays a major role in the extracellular matrix remodeling, directly by degrading several of its components and indirectly by activating pro-MMP2. FASEB J 16: 555-564, 2002.
3. Curtin K, Meinertzhagen I and Wyman R: Basigin (EMMPRIN) interacts with integrin to affect cellular architecture. J Cell Sci 118: 2649-2660, 2005. (Pubitemid 40932890)
4. Bordador LC, Li X, Toole B, Chen B, Regezi J, Zardi L, Hu Y and Ramos DM: Expression of emmprin by oral squamous cell carcinoma. Int J Cancer 85: 347-352, 2000. (Pubitemid 30030407)
5. Dang D, Atakilit A and Ramos DM: EMMPRIN modulates migration and deposition of TN-C in oral squamous cell carcinoma. Anticancer Res 28: 2049-2054, 2008.
6. Li X, Yang Y, Hu Y, Dang D, Regezi J, Schmidt BL, Atakilit A, Chen B, Ellis D and Ramos DM: αvβ6-Fyn signaling promotes oral cancer progression. J Biol Chem 278: 41646-41653, 2003.
7. Tang Y, Nakada MT, Rafferty P, Laraio J, McCabe FL, Millar H, Cunningham M, Snyder LA, Bugelski P and Yan L: Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 4: 371-377, 2006.
8. Berditchevski F, Chang S, Bodorova J and Hemler ME: Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. J Biol Chem 272: 29174-29180, 1997. (Pubitemid 27498208)
9. Wickström SA, Alitalo K and Keski-Oja J: Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 62: 5580-5589, 2002.
10. Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE: Tumor cell growth in.hibition by caveolin re-expression in human breast cancer cells. Oncogene 16: 1391-1397, 1998. (Pubitemid 28151846)
11. Felicetti F, Parolini I, Bottero L, Fecchi K, Errico MC, Raggi C, Biffoni M, Spadaro F, Lisanti MP, Sargiacomo M and Carè A: Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer 125: 1514-1522, 2009.
12. Ramos DM, But M, Regezi J, Schmidt, BL, Atakilit A, Dang D, Ellis D, Jordan R and Li X: Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol 21: 297-307, 2002. (Pubitemid 34497020)
13. Ramos DM, Dang D and Sadler S: The role of the integrin alpha v beta6 in regulating the epithelial-to-mesenchymal transition in oral cancer. Anticancer Res 29: 125-130, 2009.
14. Labrecque L, Nyalendo C, Langlois S, Durocher Y, Roghi C, Murphy G, Gingras D and Béliveau R: Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem 279: 52132-52140, 2004. (Pubitemid 39656586)
15. Murphy G, Reynolds JJ and Hembry RM: Metalloproteinases and cancer invasion and metastasis. Int J Cancer 44: 757-760, 1989.
16. Goldberg GI, Manner BL, Grant GA, Eisen AZ, Wilhelm S and He CS: Human 72-kiloDalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA 86: 8207-8211, 1989. (Pubitemid 19286028)
17. Wary KK, Mariotti A, Zurzolo C and Giancotti FG: A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 94: 625-634, 1998.
18. Huang P, Han J and Hui L: MAPK signaling in inflammation-associated cancer development. Protein Cell 1: 218-26, 2010.
19. Egawa N, Koshikawa N, Tomari T, Nabeshima K, Isobe T and Seiki M: Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J Biol Chem 281: 37576-37585, 2006. (Pubitemid 46042061)
20. Hayakawa T (2002): Multiple functions of tissue inhibitors of metalloproteinases (TIMPs): a new aspect involving osteoclastic bone resorption. J. Bone Miner Metab 20: 1-13, 2002.